APPLIED GENETIC TECHNOLOGIES CORPORATION

Basic Information

APPLIED GENETIC TECHNOLOGIES CRP
12085 RESEARCH DR, STE 110
ALACHUA, FL, 32615-0683

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    Amount: $657,699.00

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extr ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of HealthDepartment of Health and Human Services
  2. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Efficacy in a Dog Model

    Amount: $143,082.00

    DESCRIPTION (provided by applicant): Complete achromatopsia is an inherited retinal disorder characterized by severely reduced visual acuity, nystagmus, severe photophobia, a small central scotoma, e ...

    SBIR Phase I 2010 Department of Health and Human Services
  3. Molecular Breeding of Gene Therapy Vectors

    Amount: $131,711.00

    DESCRIPTION (provided by applicant): We propose to develop Gene Therapy vectors that are targeted to particular cell membrane receptors, cell types and/or tissues. Development of these precise deliver ...

    SBIR Phase I 2003 Department of Health and Human Services
  4. TREATMENT OF ANEMIA USING AAV VECTORS

    Amount: $256,725.00

    DESCRIPTION (applicant's abstract): The innovative use of AAV vector technology is proposed to develop milestones essential for the safe treatment of anemia secondary to chronic renal fai ...

    SBIR Phase I 2001 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government